EADV 2025｜特应性皮炎相关研究简述

大家好，我是Florence Vroman。我是一名医学博士，也是荷兰乌得勒支大学医学中心的博士生。我很高兴参加EADV大会并接受拓麦的采访。我着重于研究特应性皮炎，尤其是对儿童患者。我在EADV大会上有一张壁报展示，主要涉及到JAK抑制剂乌帕替尼，及其在成人特应性皮炎中的疗效和安全性。我也有一场关于度普利尤单抗的演讲，这是一种生物制剂。研究表明，我们可以成功地减少度普利尤单抗的剂量，同时在儿童患者中不丧失疗效。这是非常好的消息。我的研究有一部分涉及到BioDay登记研究，这是一个在日常实践中收集前瞻性数据的国家登记处研究。我们有很多成员。我的同事也在此次大会上做了演讲和展示。我们是一个大团队。我们做了大量的研究，你可以随时联系我们。我很高兴能谈谈我的研究。当然，我未来的研究仍会集中在儿童身上，特应性皮炎、不良反应，等等。希望未来有更多的JAK抑制剂，比如巴瑞替尼、阿布昔替尼。所以希望明年，我能回到这里，谈谈一些新的研究，或许会有新的成果展示。

Hello, everyone. My name is Florence Vroman.I'm a medical doctor and a PhD student at the UMC Utrecht in the Netherlands. I'm very happy to TalkMED and to be at EADV congress. My research focuses on the atopic dermatitis, and particularly in pediatric patients, children. I have here in the EADV a poster which focuses on upadacitinib, which is a JAK inhibitor, and the effect and safety in adults with the atopic dermatitis. I also have a presentation which focuses on dupilumab, which is a biologic and also shows that we can successfully reduce the dosage of the dupilumab in pediatric patients without losing the efficacy. So that's very good news. My research is part of the BioDay registry, which is a national registry that collects prospective data in daily practice. We have a lot of members. My colleague has also have a talk here and a presentation. We're a very big group. We do lots of research, so you can always reach to us. I'm very happy to talk about my research. Of course, my future research will still focus on children, atopic dermatitis, and more on the side effects, maybe, and hopefully in the future, also on more JAK inhibitors, like baricitinib, abrocitinib. So hopefully next year, I can come back here and talk about some new research, maybe, and also a new presentation.